What is the normal dose of a medication?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bupropion Dosing for Obesity Management

For obesity treatment, bupropion is used in combination with naltrexone as naltrexone/bupropion ER, with a typical maintenance dose of 16 mg naltrexone/180 mg bupropion twice daily after a 4-week titration period. 1

Dose Titration Schedule

The medication requires gradual dose escalation to minimize side effects: 1

  • Week 1: 8 mg naltrexone/90 mg bupropion once daily in the morning
  • Week 2: 8 mg naltrexone/90 mg bupropion twice daily (morning and evening)
  • Week 3: 16 mg naltrexone/180 mg bupropion in the morning, 8 mg naltrexone/90 mg bupropion in the evening
  • Week 4 and beyond: 16 mg naltrexone/180 mg bupropion twice daily (maintenance dose)

Expected Weight Loss Outcomes

Clinical trials demonstrate the following weight loss results with the maintenance dose: 1

  • COR-I trial: 6.1% weight loss versus 1.3% with placebo
  • COR-II trial: 6.4% weight loss versus 1.8% with placebo
  • COR-DIABETES trial: 5.1% weight loss in diabetic patients

Ideal Patient Selection

This medication works particularly well for patients with: 1

  • Food cravings or addictive eating behaviors
  • Concomitant depression (bupropion component provides antidepressant effects)
  • Desire to quit smoking or reduce alcohol intake
  • Preference for non-controlled substances and oral (non-injectable) medications

Critical Contraindications

Absolute contraindications include: 1

  • Uncontrolled hypertension
  • History of seizures or conditions predisposing to seizures
  • Anorexia nervosa or bulimia nervosa
  • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
  • Recent MAOI use (within 14 days)
  • Uncontrolled pain requiring chronic opioid therapy

Important Safety Monitoring

Patients require close monitoring for mood changes, particularly in the first few months of treatment, though phase 3 studies reported no evidence of suicidality. 1 Blood pressure should be monitored regularly given the potential for hypertensive effects.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.